Published in Blood on February 13, 2003
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Dysregulation of coagulation in cerebral malaria. Mol Biochem Parasitol (2009) 1.29
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling. J Thromb Haemost (2011) 1.18
Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke (2008) 1.15
Protein C anticoagulant and cytoprotective pathways. Int J Hematol (2012) 1.14
Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci (2012) 1.13
Activated protein C: biased for translation. Blood (2015) 1.05
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des (2013) 1.03
Immune mechanisms and novel pharmacological therapies of acute kidney injury. Curr Drug Targets (2009) 1.02
Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res (2010) 1.00
Pathogenesis of acute kidney injury: foundation for clinical practice. Am J Kidney Dis (2011) 0.98
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des (2012) 0.98
The protein C pathway and pathologic processes. J Thromb Haemost (2009) 0.97
Drotrecogin alfa (activated) may attenuate severe sepsis-associated encephalopathy in clinical septic shock. Crit Care (2010) 0.95
Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci (2010) 0.93
Induction of MMP-9 release from human dermal fibroblasts by thrombin: involvement of JAK/STAT3 signaling pathway in MMP-9 release. BMC Cell Biol (2007) 0.91
Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. Exp Cell Res (2009) 0.91
Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem (2008) 0.88
Activated protein C: a potential cardioprotective factor against ischemic injury during ischemia/reperfusion. Am J Transl Res (2009) 0.88
Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease. J Cereb Blood Flow Metab (2015) 0.86
Roles of inflammation and the activated protein C pathway in the brain edema associated with cerebral venous sinus thrombosis. Stroke (2009) 0.85
Combined neurothrombectomy or thrombolysis with adjunctive delivery of 3K3A-activated protein C in acute ischemic stroke. Front Cell Neurosci (2015) 0.80
Haplotypes of the endothelial protein C receptor (EPCR) gene are not associated with severe malaria in Tanzania. Malar J (2015) 0.77
Safety threshold of intravitreal activated protein-C. Graefes Arch Clin Exp Ophthalmol (2010) 0.76
A Linear Temporal Increase in Thrombin Activity and Loss of Its Receptor in Mouse Brain following Ischemic Stroke. Front Neurol (2017) 0.75
Analysis of endothelial protein C receptor functionality on living cells'. Open Biochem J (2009) 0.75
Single nucleotide variants in the protein C pathway and mortality in dialysis patients. PLoS One (2014) 0.75
Activated protein C induces endoplasmic reticulum stress and attenuates lipopolysaccharide-induced apoptosis mediated by glycogen synthase kinase-3β. Mediators Inflamm (2012) 0.75
Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury. PLoS One (2017) 0.75
The cytoprotective protein C pathway. Blood (2006) 5.75
Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron (2010) 5.20
LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron (2004) 4.29
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature (2012) 3.80
ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci (2008) 3.78
apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest (2008) 3.36
Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab (2006) 3.35
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest (2012) 2.98
Regulation of fluid and electrolyte secretion in salivary gland acinar cells. Annu Rev Physiol (2005) 2.94
Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol (2009) 2.85
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 2.81
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med (2005) 2.71
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem (2004) 2.45
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med (2004) 2.45
Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med (2007) 2.32
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res (2007) 2.17
Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proc Natl Acad Sci U S A (2007) 1.91
Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J (2003) 1.91
RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke (2004) 1.89
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat Cell Biol (2008) 1.83
IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J Neurosci (2005) 1.69
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Coupling of angiogenesis and neurogenesis in cultured endothelial cells and neural progenitor cells after stroke. J Cereb Blood Flow Metab (2007) 1.64
Myocardin is sufficient for a smooth muscle-like contractile phenotype. Arterioscler Thromb Vasc Biol (2008) 1.62
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol Neurodegener (2010) 1.49
Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost (2008) 1.49
Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease. Brain Pathol (2012) 1.45
Expression and function of the endothelial protein C receptor in human neutrophils. Blood (2003) 1.45
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A (2008) 1.45
Effect of hyperhomocysteinemia on protein C activation and activity. Blood (2002) 1.45
A simple method for isolation and characterization of mouse brain microvascular endothelial cells. J Neurosci Methods (2003) 1.44
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Activated protein C induces endothelial cell proliferation by mitogen-activated protein kinase activation in vitro and angiogenesis in vivo. Circ Res (2004) 1.40
Neurodegeneration and the neurovascular unit. Nat Med (2010) 1.37
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A (2012) 1.34
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
Neurovascular dysfunction and faulty amyloid β-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.32
Induction of long-term lipopolysaccharide tolerance by an agonistic monoclonal antibody to the toll-like receptor 4/MD-2 complex. Clin Vaccine Immunol (2006) 1.31
High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation (2005) 1.31
Protein S controls hypoxic/ischemic blood-brain barrier disruption through the TAM receptor Tyro3 and sphingosine 1-phosphate receptor. Blood (2010) 1.30
Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem (2002) 1.30
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J (2009) 1.27
Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol (2005) 1.26
MCMC estimation of Markov models for ion channels. Biophys J (2011) 1.25
Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood (2003) 1.21
Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol (2012) 1.19
Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice. J Neurosci Methods (2004) 1.19
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke (2008) 1.15
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis (2003) 1.15
Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A (2014) 1.14
Protein C anticoagulant and cytoprotective pathways. Int J Hematol (2012) 1.14
Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability. J Cereb Blood Flow Metab (2012) 1.13
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes (2004) 1.11
Irbit mediates synergy between ca(2+) and cAMP signaling pathways during epithelial transport in mice. Gastroenterology (2013) 1.10
Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cereb Blood Flow Metab (2008) 1.10
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost (2009) 1.10
Activated protein C induces the release of microparticle-associated endothelial protein C receptor. Blood (2004) 1.09
A kinetic model for type I and II IP3R accounting for mode changes. Biophys J (2012) 1.08
Brain capillary endothelium and choroid plexus epithelium regulate transport of transferrin-bound and free iron into the rat brain. J Neurochem (2004) 1.08
Neurovascular defects and faulty amyloid-β vascular clearance in Alzheimer's disease. J Alzheimers Dis (2013) 1.07
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol (2002) 1.07
Generation and phenotypic analysis of protein S-deficient mice. Blood (2009) 1.06
Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target (2002) 1.06
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci (2002) 1.06
Microparticle-associated endothelial protein C receptor and the induction of cytoprotective and anti-inflammatory effects. Haematologica (2009) 1.05
Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. J Cereb Blood Flow Metab (2016) 1.05
Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol (2013) 1.04
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des (2013) 1.03
Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol (2011) 1.02